Kymera Therapeutics KYMR 深 沪
交易中 10-06 10:36:00 美东时间
102.90
-6.950
-6.33%
华盛通- 最 高127.85
- 今 开111.03
- 成交量 23.05万股
- 最 低 102.87
- 昨 收 109.85
- 总市值 532.24万
- 52周最高 130.05
- 市盈率 静 --
- 换手率 445.66%
- 52周最低 55.2601
- 委 比 79.49%
- 总股本 5.17万
- 历史最高 130.05
- 量 比 2.28
- 振 幅 22.74%
- 历史最低 1.10
- 每 手 1
- 风险率 19.46%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Wolfe Research Upgrades Kymera Therapeutics to Outperform
Wolfe Research analyst Andy Chen upgrades Kymera Therapeutics (NASDAQ:KYMR) from Peer Perform to Outperform.
09-10 21:36
Earnings Scheduled For April 30, 2026
Companies Reporting Before The Bell • Sonic Automotive (NYSE:SAH) is projected ...
04-30 19:11
Gilead Expands Tempus AI Partnership To Boost Oncology Pipeline
Gilead expands Tempus AI deal and licenses Kymera's KT-200, advancing oncology pipeline with data, analytics and drug development.
04-10 01:14
Analyst Expectations For Kymera Therapeutics's Future
22 analysts have expressed a variety of opinions on Kymera Therapeutics (NASDAQ...
02-27 04:01
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
Kymera Stock Smashes 52-Week High As New Pill Crushes Eczema Markers
Kymera Therapeutics released positive clinical results for KT-621 for atopic dermatitis and other allergic diseases.
2025-12-08 22:54
Market-Moving News for December 8th
FULC: 66% | Fulcrum Therapeutics Announced Saturday, Initial Results From 20 mg Dose Cohort Of The Phase 1b PIONEER Trial Of Pociredir In Sickle Cell Disease; Clear Dose-response Observed, With Robust, Clinically
2025-12-08 20:34
【国盛医药】周专题&周观点：从海外映射寻找下半年创新药新赛道
（转自：国医盛视） 一、医药核心观点 当周（6.30-7.04）回顾与周专题： 当周（6.30-7.04）申万医药指数环比+3.64%...
2025-07-06 20:38
Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
Kymera Therapeutics announced positive results from the Phase 1 study of KT-621, an oral STAT6 degrader, showing robust STAT6 degradation, favorable safety profile, and encouraging Th2 biomarker reductions. The drug is expected to advance into Phase 2b trials in AD and asthma in late 2025 and early 2026.
2025-06-02 11:00
